Who Optimizes SG&A Costs Better? Genmab A/S or Viking Therapeutics, Inc.

Optimizing SG&A Costs: A Tale of Two Companies

In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Genmab A/S and Viking Therapeutics, Inc. have taken different paths in optimizing these costs.

Genmab A/S: A Steady Climb

From 2014 to 2023, Genmab A/S has seen a significant increase in SG&A expenses, growing by over 4,000%. This rise reflects the company's aggressive expansion and investment in administrative capabilities. By 2023, their SG&A expenses reached a peak, indicating a robust growth strategy.

Viking Therapeutics, Inc.: A Conservative Approach

In contrast, Viking Therapeutics, Inc. has maintained a more conservative approach, with SG&A expenses increasing by approximately 2,900% over the same period. This strategy suggests a focus on lean operations, potentially allowing for more flexibility in resource allocation.

Both companies showcase distinct strategies in managing SG&A costs, offering valuable insights into their operational priorities.